| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
No specific biological target. HO-PEG-CH2COOH (MW 10000) is a synthetic polymer, not a pharmacologically active compound. It does not bind to receptors or enzymes. Its primary use is as a PEGylation reagent to modify drugs, proteins, or nanoparticles. PEGylation imparts benefits such as increased solubility, reduced immunogenicity, extended circulation half-life, and decreased proteolysis. The 10 kDa size is commonly used for conjugation to small molecules or peptides where a moderate increase in molecular weight is desired. The PEG spacer provides flexibility and hydrophilicity. The carboxylic acid end allows site-specific conjugation. The hydroxyl end can be capped or used for further chemistry. This product is a tool for drug delivery research.
|
|---|---|
| ln Vitro |
Not applicable. HO-PEG-CH2COOH (MW 10000) itself has no direct biological activity. It is not used in in vitro assays to inhibit enzymes or affect cell function. At typical concentrations used in conjugation (0.1-10 mg/mL), it is non-toxic and does not interfere with cell growth or signaling. Its purpose is to be coupled to active molecules. After conjugation, the PEG moiety may alter the activity (e.g., reduce potency due to steric hindrance) but enhance pharmacokinetics. As a reagent, it is not evaluated for in vitro efficacy.
|
| ln Vivo |
Not applicable. The polymer is not administered alone in vivo. When conjugated to a drug or protein, the conjugate can be dosed. For example, a PEG10k-cytokine conjugate may show improved half-life and reduced immunogenicity. In preclinical studies, high molecular weight PEGs (10 kDa) have a plasma half-life of several hours to days in mice (dependent on species and dose). They are generally well-tolerated but may cause vacuolation in renal tubules at high doses. The compound is for research use as a linker; it is not a therapeutic.
|
| Enzyme Assay |
For quality control, the PEG can be characterized by GPC (gel permeation chromatography) to confirm molecular weight and polydispersity. Carboxylic acid content can be quantified by titration or by a colorimetric assay (e.g., using Toluidine Blue O). Activation to NHS ester is typically verified by reaction with a small amine (e.g., ethylamine) and detection of the amide by FTIR or HPLC. For conjugation to a model protein (e.g., lysozyme or BSA), dissolve PEG-COOH (10 kDa) in MES buffer (pH 5.5) with EDC (5-10 eq) and NHS (5-10 eq), activate for 15-30 min. Add the protein in PBS (pH 7.4) at a molar ratio of 1:1 to 1:10 (protein:PEG). Incubate 2-4 h. Purify by dialysis or ultrafiltration. Analyze conjugation efficiency by SDS-PAGE or MALDI-TOF. No direct receptor binding assay is performed.
|
| Cell Assay |
Not applicable. HO-PEG-CH2COOH (MW 10000) is not used directly in cell-based assays. It can be used to PEGylate cell surfaces or to prepare PEG-coated nanoparticles. For a typical conjugation to a peptide, the peptide is dissolved in PBS (pH 7.4). The PEG-COOH is activated separately as described above, then added to the peptide solution. After incubation, purify the PEGylated peptide by HPLC or size exclusion. The PEGylated product can then be tested in cell-based assays for activity (e.g., receptor binding or signaling). However, the PEG linker itself is inert. For cell viability assays, the unreacted PEG (up to 10 mg/mL) shows no cytotoxicity in most cell lines. For research use, follow standard conjugation protocols.
|
| Animal Protocol |
Not applicable. The compound is not administered in vivo as a standalone agent. For a PEGylated drug candidate, the conjugate can be dosed in animals. For example, a PEG10k-anti-cancer peptide conjugate may be injected intravenously into tumor-bearing mice at 10-50 mg/kg. The PEG10k linker helps to extend the half-life of the peptide. In such studies, vehicle control groups might receive PBS. However, the unconjugated PEG is not administered. There is no standard in vivo protocol for HO-PEG-CH2COOH alone. For safety studies, PEG 10 kDa administered intravenously in rats at 1 g/kg causes transient renal vacuolation but is not lethal. For research, it is a conjugation reagent.
|
| ADME/Pharmacokinetics |
For PEG with MW 10,000 Da, the pharmacokinetics in rodents: after intravenous injection, the plasma half-life is 2-6 hours, which is shorter than that of 35 kDa PEG (days) because 10 kDa is closer to the renal filtration cutoff (≈30-40 kDa). In mice, the t1/2 of 10 kDa PEG is approximately 4-8 hours. The volume of distribution is low (≈50-100 mL/kg). It is not metabolized; it is excreted primarily in urine. The compound does not cross the blood-brain barrier. When conjugated to a drug, the PK of the conjugate is dominated by the PEG moiety. For PK analysis, quantify PEGylated drug by ELISA or LC-MS. The product is a reagent, not a drug; no internal PK data are required for research use.
|
| Toxicity/Toxicokinetics |
PEG 10,000 Da is generally recognized as safe (GRAS) for use in pharmaceutical formulations at low concentrations (<1% w/v). In preclinical toxicology, high doses (≥500 mg/kg i.v.) may cause mild renal tubular vacuolation in rats, which is reversible. No genotoxicity or carcinogenicity is associated with PEG. Acute toxicity is very low (LD50 >10 g/kg in rodents). The compound is not intended for human use as a drug; it is a research chemical. Standard safety precautions (gloves, lab coat) should be taken. Avoid ingestion and inhalation. This product is for research use only.
|
| References | |
| Additional Infomation |
HO-PEG-CH2COOH (MW 10000) is a heterobifunctional PEG linker widely used in bioconjugation and drug delivery. It allows for the attachment of drugs, peptides, and proteins via the carboxylic acid end (activated as NHS ester) while the hydroxyl end remains inert or can be further modified. Compared to the 35 kDa version, the 10 kDa PEG provides a shorter chain, which may be advantageous for certain applications (e.g., lower viscosity, easier characterization). The product is supplied as a white powder and should be stored dry at -20degC or 4degC. It is for research use only and is not an FDA-approved drug. It is a standard laboratory reagent.
|
| Molecular Weight |
10000.00
|
|---|---|
| Appearance |
Solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~10.00 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (0.25 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (0.25 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (0.25 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.1000 mL | 0.5000 mL | 1.0000 mL | |
| 5 mM | 0.0200 mL | 0.1000 mL | 0.2000 mL | |
| 10 mM | 0.0100 mL | 0.0500 mL | 0.1000 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
